Clinical Trial: A Study of Pemetrexed in Small Cell Lung Cancer, Which Has Returned
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: Phase II Trial of ALIMTA in Relapsed Small Cell Lung Cancer
Brief Summary: The purposes of this study are to determine 1) the safety of pemetrexed and any side effects that might be associated with it 2) whether pemetrexed can help patients with small cell lung cancer live longer 3) whether pemetrexed can make tumors smaller or disappear and for how long and 4) to see if patients feel better while taking pemetrexed
Detailed Summary:
Sponsor: Eli Lilly and Company
Current Primary Outcome: To assess the antitumor activity for patients with both sensitive and refractory small cell lung cancer patients as measured by tumor response rate. To characterize the toxicities of pemetrexed in this patient population
Original Primary Outcome: Same as current
Current Secondary Outcome: To better understand any side effects of pemetrexed
Original Secondary Outcome: Same as current
Information By: Eli Lilly and Company
Dates:
Date Received: September 12, 2005
Date Started: July 2004
Date Completion: September 2006
Last Updated: January 24, 2007
Last Verified: January 2007